From: 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
Patient # | Age at surgery / Gender | Ethnicity | cTNM | cStage | WHO classd | Time of diagnosisa | Initial treatment | Open procedure / Timeb | Follow-upc (months) |
---|---|---|---|---|---|---|---|---|---|
P1 | 61.9 / M | Caucasian | T2N2M0 | Stage 3 | III | 24.4 | 60 Gy to nasopharynx | No | 56.4 |
P2 | 50.3 / M | Taiwanese | T1N2M0 | Stage 3 | III | 48.5 | 70 Gy to nasopharynx, 50 Gy to neck + chemo (5-FU, cisplatin) | No | 57.2 |
P3 | 45.8 / M | Chinese | T1N0M0 | Stage 1 | II | 36.2 | IMRT (70 Gy to nasopharynx, 54 Gy to neck) | No | 70.7 |
P4 | 60.4 / F | Japanese | T2N1M0 | Stage 2 | II | 54.2 | IMRT (70 Gy) + Chemo (cisplatin, 5-FU) | Yes / 36.7 | 70.5 |
P5 | 60.4 / M | African American | T1N0M0 | Stage 1 | III | 5.2 | IMRT (70 Gy to nasopharynx, 54 Gy to neck) | No | 94.9 |
P6 | 80.8 / F | Chinese | T1N0M0 | Stage 1 | III | 13.1 | IMRT (70 Gy) | No | 93.6 |
P7 | 34.9 / F | Taiwanese | T3N1M0 | Stage 3 | II | 24.8 | IMRT (70 Gy) + Chemo (cisplatin, 5-FU, bevacizumab) | No | 89.1 |
P8 | 70.5 / M | Taiwanese | T3N0M0 | Stage 3 | III | 168 | External beam radiation | Yes / 86.8 | 96 |
P9 | 63.8 / M | Filipino | T1N1M0 | Stage 2 | III | 24.0 | IMRT (66.6 Gy to nasopharynx, 59.4 Gy to neck) + Chemo (cisplatin) | No | 86 |
P10 | 69.9 / M | Filipino | T1N1M0 | Stage 2 | II | 13.0 | IMRT (70 Gy to nasopharynx, 56.4 Gy to neck) | No | 67.2 |
P11 | 42.5 / M | Chinese | T1N3M0 | Stage 4a | III | 84.7 | 70 Gy to nasopharynx, 72 Gy to neck + Chemo (5-FU, cisplatin) | Yes / 36.4 | 60.6 |
P12 | 45.5 / M | Chinese | T1N2M0 | Stage 3 | III | 4.2 | IMRT (70 Gy) + Chemo (5-FU, cisplatin) | No | 82.2 |
P13 | 44.6 / F | Chinese | T1N2M0 | Stage 3 | I | 156 | Radiation + Chemo | Yes / 145 | 78.2 |